1. Defibrotide for the treatment of PIMS-TS in two pediatric patients
- Author
-
Lang, Peter, Eichholz, Thomas, Bakchoul, Tamam, Streiter, Monika, Petrasch, Maurice, Bösmüller, Hans, Klein, Reinhild, Rabsteyn, Armin, Lang, Anne-Marie, Adams, Constantin, Klingel, Karin, Gessner, Michaela, Rosenberger, Peter, Ruef, Peter, and Handgretinger, Rupert
- Subjects
Adolescent ,Fever ,SARS-CoV-2 ,Brief Report ,T-Lymphocytes ,Pneumonia, Viral ,COVID-19 ,defibrotide ,Blood Coagulation Factors ,Systemic Inflammatory Response Syndrome ,endotheliitis ,Abdominal Pain ,Betacoronavirus ,AcademicSubjects/MED00290 ,Polydeoxyribonucleotides ,children ,Humans ,complement ,Female ,AcademicSubjects/MED00670 ,Child ,Coronavirus Infections ,Pandemics ,Platelet Aggregation Inhibitors - Abstract
The pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 infection is a severe complication of coronavirus disease 2019. Since impaired coagulation and thrombosis/endotheliitis are suspected pathomechanisms, we treated 2 patients with defibrotide, a profibrinolytic, antithrombotic, antiinflammatory oligonucleotide. Symptoms resolved during treatment. Moreover, coagulation parameters indicating hypofibrinolysis and complement activation normalized. The pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus 2 infection is a severe complication of coronavirus disease 2019. Since impaired coagulation and thrombosis/endotheliitis are suspected pathomechanisms, 2 patients received defibrotide, a profibrinolytic, antithrombotic, antiinflammatory oligonucleotide. Symptoms resolved and hypofibrinolysis/complement activation normalized during treatment.
- Published
- 2020